Core Insights - Healthcare and biotechnology stocks experienced significant movements in after-hours trading, with several companies showing strong gains despite limited news flow [1] Company Summaries - Novo Nordisk A/S (NVO) saw a notable increase of 9.48%, closing at $52.66, following FDA approval of its Wegovy pill, the first oral GLP-1 medicine for obesity in the U.S., which is also approved to reduce cardiovascular risks [2] - Neumora Therapeutics, Inc. (NMRA) advanced 16.02% to $2.10, indicating investor interest possibly driven by broader sector momentum or speculative trading, as there were no specific news updates [3] - BioRestorative Therapies, Inc. (BRTX) rose 6.90% to $1.24, with investors reacting to a prior announcement regarding an FDA Type B meeting to discuss a potential accelerated BLA pathway for its BRTX-100 program for chronic lumbar disc disease [4] - RenovoRx, Inc. (RNXT) added 4.44% to close at $0.94, with earlier news of an accepted abstract submission for the ASCO Gastrointestinal Cancers Symposium 2026 contributing to investor interest [5] - IDEAYA Biosciences, Inc. (IDYA) gained 6.49% to $37.81, following the full enrollment of 435 patients in its Phase 2/3 trial for darovasertib, with expected data reporting in Q1 2026 [6] - Healthcare Triangle, Inc. (HCTI) climbed 6.72% to $1.43, with a recent announcement of an Advance Agreement for acquiring AI-powered customer experience firms, enhancing its position in global AI-driven solutions [7] - Alphatec Holdings, Inc. (ATEC) posted a modest gain of 2.80%, rising to $21.28, benefiting from ongoing investor confidence in the spine surgery provider [8]

Core Insights - Several small-cap biotech and therapeutics companies experienced significant gains in after-hours trading, driven by earnings updates, financial guidance, and regulatory developments [1] Company Summaries - Inotiv, Inc. (NOTV) saw a 36.61% increase in after-hours trading to $0.94, recovering from a 33.20% decline at the close, following preliminary Q4 revenue expectations of $137.5 million to $138.5 million and full-year revenue projections of $512.5 million to $513.5 million [2] - Applied Therapeutics, Inc. (APLT) rose 16.89% to $0.33 after a 30.19% gain at the close, with investors reacting positively to a narrower Q3 net loss of $19.0 million, or $0.13 per share, compared to a $68.6 million loss, or $0.48 per share, in the same quarter last year [3] - Alumis Inc. (ALMS) advanced 7.09% to $5.97, despite reporting a Q3 net loss of $110.8 million, wider than the $93.1 million loss in the prior year, with $2.1 million in collaboration income potentially boosting investor confidence [4] - TELA Bio, Inc. (TELA) increased 7.89% to $1.23 after a 14.08% gain at the close, reporting a reduced Q3 net loss of $8.6 million compared to $10.4 million a year earlier, with revenue growth of 9% to $20.7 million and revised 2025 guidance projecting at least 16% revenue growth over 2024 [5] - Corcept Therapeutics Inc. (CORT) gained 4.90% to $78.80, reflecting continued investor interest despite no specific news released [6] - BioRestorative Therapies, Inc. (BRTX) jumped 8.06% to $1.34, rebounding from a 6.77% decline at the close, following the announcement of a Type B meeting with the FDA to discuss a potential accelerated Biologics License Application pathway for its BRTX-100 program [7]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Company Performance - Black Diamond (BDTX) has returned 29% year-to-date, significantly outperforming the average return of -3% for Medical companies [4] - The Zacks Consensus Estimate for BDTX's full-year earnings has increased by 37.3% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [3] - Biorestorative Therapies, Inc. (BRTX) has also shown strong performance, with a year-to-date increase of 6.3% and a consensus EPS estimate increase of 12.5% over the past three months [4][5] Industry Context - Black Diamond is part of the Medical - Biomedical and Genetics industry, which includes 487 stocks and currently ranks 146 in the Zacks Industry Rank [6] - The Medical - Biomedical and Genetics industry has gained an average of 4.1% so far this year, indicating that BDTX is performing better than its industry peers [6] - The Medical sector, which includes 976 individual stocks, holds a Zacks Sector Rank of 7, suggesting a relatively weaker performance compared to other sectors [2]

Company Performance - Zymeworks Inc. reported quarterly earnings of $0.03 per share, exceeding the Zacks Consensus Estimate of a loss of $0.52 per share, and showing improvement from a loss of $0.26 per share a year ago, resulting in an earnings surprise of +105.77% [1] - The company achieved revenues of $48.73 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 256.65%, compared to revenues of $19.24 million in the same quarter last year [2] - Over the last four quarters, Zymeworks has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - Zymeworks shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $27.89 million, and for the current fiscal year, it is -$1.64 on revenues of $100.05 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Zymeworks belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zymeworks' stock performance [5]

Company Performance - Entrada Therapeutics reported a quarterly loss of $1.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.86, and a significant decline from earnings of $1.55 per share a year ago, indicating an earnings surprise of -20.93% [1] - The company posted revenues of $1.95 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 78.02%, and a sharp decline from year-ago revenues of $94.69 million [2] - Over the last four quarters, Entrada Therapeutics has surpassed consensus EPS estimates three times, but has underperformed the market with shares losing about 66.3% since the beginning of the year [2][3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.93 on revenues of $8.54 million, and for the current fiscal year, it is -$3.18 on revenues of $44.01 million [7] - The estimate revisions trend for Entrada Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6] Industry Context - Entrada Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Market Performance - The three major US stock indices closed lower, with the Dow Jones down 0.94%, the S&P 500 down 0.79%, and the Nasdaq down 0.92% [1] - Most large tech stocks declined, with Tesla dropping over 6%, Apple down more than 1%, Google down over 1%, Nvidia down 0.69%, Microsoft down 0.22%, Facebook down 0.09%, while Amazon rose 0.03% [1] - Popular Chinese concept stocks mostly rose, with Bit Digital up over 18%, Bilibili up more than 7%, and others like Ado, Ctrip, and Baidu also showing gains [1] - European stock indices had mixed results, with Germany's DAX up 1.2%, France's CAC40 up 0.35%, and the UK's FTSE 100 down 0.19% [1] Commodity Prices - International precious metal futures had mixed results, with COMEX gold futures up 0.10% at $3346.40 per ounce, while COMEX silver futures fell 0.39% to $36.94 per ounce [1] - International oil prices increased, with the main US oil contract up 1.37% at $67.92 per barrel and Brent crude up 1.84% at $69.56 per barrel [1] Currency and Bond Markets - The US dollar index rose 0.58% to 97.55, while the offshore RMB fell 150 basis points against the dollar to 7.1796 [1] - US Treasury yields collectively increased, with the 2-year yield up 1.04 basis points to 3.890%, and the 10-year yield up 3.56 basis points to 4.377% [1] - European bond yields also rose, with the UK 10-year yield up 3.2 basis points to 4.584%, and the German 10-year yield up 3.6 basis points to 2.641% [1]

MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Tuesday, April 15, 2025Time: 10:50 a.m. Eastern Time ...

MELVILLE, N.Y., April 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Tuesday, April 15, 2025, at 10:50 a.m. Eastern time. Benzinga All-Access Show Date: Tuesday, April 15, 2025Time: 10:50 a.m. Eastern Time ...

MELVILLE, N.Y., April 10, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to confirm that it currently faces no material exposure to newly imposed U.S. tariffs. BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow, is BioRestorative’s lead clinical candidate. The safety and effi ...